{"nctId":"NCT01516424","briefTitle":"Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone","startDateStruct":{"date":"2012-02"},"conditions":["Schizophrenia"],"count":267,"armGroups":[{"label":"Blonanserin","type":"EXPERIMENTAL","interventionNames":["Drug: Blonanserin"]},{"label":"Risperidone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Risperidone"]}],"interventions":[{"name":"Blonanserin","otherNames":["Lonasen"]},{"name":"Risperidone","otherNames":["Risperdal"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject met Diagnostic and Statistical Manual of Mental Disorders(DSM)-IV-Text Revision(TR) criteria for a primary diagnosis of schizophrenia\n* Patients are 18≤age\\<65 years of age on the day when informed consent is obtained.\n* Subject had a PANSS total score ≥70 and 120≥ at Screening\n* Subject had a score ≥4 on the PANSS at Screening and Baseline.\n* Subjects are willing and able to comply with study protocol including treatment in hospital.\n* Subjects or their legal guardians have signed the written informed consent form.\n\nExclusion Criteria:\n\n* The subject was treatment with other Investigate product within 30 days.\n* Subject had a history of treatment with long-acting drug for anti schizophrenia within 56 days.\n* Subject had a history of treatment with clozapine within 28 days.\n* Subject With parkinson disease,etc","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in PANSS(Positive and Negative Syndrome Scale) Total Score at Week 8","description":"Mean change in Positive and Negative Syndrome Scale total score from baseline to Week 8 at the end of treatment. PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. It have 30 evaluation items, which include 7 positive sub-scale, 7 negative sub-scale and 16 general psychopathology sub-scale on a score of 1 to 7. The total score is the sum of the 30 scale items. The minimum score is 30 and the maximum score is 210. Patient with PANSS total scores\\<70 is the normal,but the scores\\>120 is more serious.Change=(Week 8 Score - Baseline score)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.59","spread":"18.53"},{"groupId":"OG001","value":"-33.56","spread":"16.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.71","spread":"17.02"},{"groupId":"OG001","value":"-36.31","spread":"14.09"}]}]}]},{"type":"SECONDARY","title":"Mean Change in PANSS Subscale Score at the End of Treatment","description":"Mean Change in PANSS subscale score at the end of treatment at 8 weeks the frame of 8 weeks is from baseline","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Mean Change in PANSS 5-factor Model","description":"Mean change in PANSS 5-factor model from baseline at Week 8","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Mean Change in PANSS Symptom Scores","description":"Mean change in PANSS symptom scores from baseline at Week 8","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Mean Change in PANSS Symptom Scores From Baseline at Each Visit","description":"Mean change in PANSS symptom scores from baseline at each Visit from baseline at week 8","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":130},"commonTop":["Serum prolactin increase","Extrapyramidal disorders","Excitement","constipation","Insomnia"]}}}